SG11202109535SA - Cd3 binding molecules - Google Patents

Cd3 binding molecules

Info

Publication number
SG11202109535SA
SG11202109535SA SG11202109535SA SG11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA SG 11202109535S A SG11202109535S A SG 11202109535SA
Authority
SG
Singapore
Prior art keywords
binding molecules
molecules
binding
Prior art date
Application number
Inventor
Loo Pieter Fokko Van
Original Assignee
Merus Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merus Nv filed Critical Merus Nv
Publication of SG11202109535SA publication Critical patent/SG11202109535SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SG11202109535S 2019-03-29 2020-03-27 Cd3 binding molecules SG11202109535SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19166345 2019-03-29
EP19200931 2019-10-01
PCT/NL2020/050214 WO2020204708A1 (en) 2019-03-29 2020-03-27 Cd3 binding molecules

Publications (1)

Publication Number Publication Date
SG11202109535SA true SG11202109535SA (en) 2021-10-28

Family

ID=70057206

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109535S SG11202109535SA (en) 2019-03-29 2020-03-27 Cd3 binding molecules

Country Status (12)

Country Link
US (1) US20220356251A1 (en)
EP (1) EP3947456A1 (en)
JP (2) JP2022527935A (en)
KR (1) KR20210145136A (en)
AU (1) AU2020254215A1 (en)
BR (1) BR112021018632A2 (en)
CA (1) CA3133624A1 (en)
IL (1) IL286013A (en)
MX (1) MX2021010877A (en)
SG (1) SG11202109535SA (en)
TW (1) TW202039578A (en)
WO (1) WO2020204708A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165813A1 (en) * 2022-03-01 2023-09-07 Technische Universität Darmstadt "two-in-one"-antibodies binding to egfr/pd-l1-double positive cells
EP4238992A1 (en) * 2022-03-01 2023-09-06 Technische Universität Darmstadt Two in one - antibodies binding to egfr/pd-l1-double positive cells
WO2023213998A1 (en) 2022-05-06 2023-11-09 Ichnos Sciences SA Cd3/bcma/cd38 trispecific antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368733T3 (en) 2002-07-18 2011-11-21 Merus B.V. RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES.
US7728114B2 (en) * 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
WO2007145941A2 (en) * 2006-06-06 2007-12-21 Tolerrx, Inc. Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2288715B1 (en) 2008-04-11 2014-09-24 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2147594B1 (en) 2008-06-27 2013-11-13 Merus B.V. Antibody producing non-human mammals
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
CA2791109C (en) * 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
MX360109B (en) 2012-04-20 2018-10-23 Merus Nv Methods and means for the production of ig-like molecules.
JOP20200236A1 (en) 2012-09-21 2017-06-16 Regeneron Pharma Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof
SI2900694T1 (en) 2012-09-27 2018-12-31 Merus N.V. Bispecific igg antibodies as t cell engagers
CN108026174B (en) 2015-07-10 2023-02-17 美勒斯公司 Human CD3 binding antibodies
US10221242B2 (en) * 2016-01-21 2019-03-05 Pfizer Inc. Antibodies specific for epidermal growth factor receptor variant III and their uses
CN111936514A (en) 2018-03-30 2020-11-13 美勒斯公司 Multivalent antibodies

Also Published As

Publication number Publication date
MX2021010877A (en) 2021-10-22
WO2020204708A1 (en) 2020-10-08
TW202039578A (en) 2020-11-01
BR112021018632A2 (en) 2021-11-23
KR20210145136A (en) 2021-12-01
CA3133624A1 (en) 2020-10-08
IL286013A (en) 2021-10-31
JP2022527935A (en) 2022-06-07
AU2020254215A1 (en) 2021-09-30
EP3947456A1 (en) 2022-02-09
US20220356251A1 (en) 2022-11-10
JP2023179541A (en) 2023-12-19

Similar Documents

Publication Publication Date Title
ZA202203250B (en) Cd3 binding antibodies
IL263840A (en) Cd3 binding antibodies
IL283635A (en) Binding molecules against cd3 and uses thereof
IL281901A (en) Multivalent igm- and iga-fc-based binding molecules
IL277848A (en) Her2-targeting antigen binding molecules comprising 4-1bbl
GB201901306D0 (en) Multi-domain binding molecules
IL286013A (en) Cd3 binding molecules
IL287555A (en) Binding molecules
GB201811410D0 (en) OX40 Binding molecules
IL288314A (en) Anti-tdp-43 binding molecules and uses thereof
IL284926A (en) Cd3-specific binding molecules
IL292698A (en) N-terminal scfv multispecific binding molecules
IL289415A (en) Claudin-6 binding molecules and uses thereof
GB201811408D0 (en) CD137 Binding Molecules
EP3781204A4 (en) Binding molecules
IL288561A (en) Anti-gal9 immune-inhibiting binding molecules
IL288562A (en) Activating anti-gal9 binding molecules
GB201906118D0 (en) Anti-LAG-3 binding molecules
GB202010329D0 (en) Specific binding molecules
EP3941947A4 (en) Anti-her2 binding molecules
GB201803178D0 (en) Specific binding molecules for htert
GB201914468D0 (en) Binding Molecules
GB201912030D0 (en) Binding molecules
GB201915282D0 (en) Specific binding molecules
GB201906870D0 (en) Binding molecules